The global neurodegenerative disease market size is valued at USD 59.06 billion in 2025 and is estimated to grow from USD 63.25 billion in 2026 to USD 109.73 billion by 2034, growing at a CAGR of 7.10% during the forecast period (2026–2034). North America dominated the neurodegenerative disease market with a market share of 42.35% in 2025.
Neurodegenerative diseases are disorders that gradually damage or destroy nerve cells in the brain and nervous system, leading to problems with memory, movement, thinking, and daily activities. Common examples include Alzheimer's disease, Parkinson's disease, and Huntington's disease. Demand for related treatments is growing due to the aging population, increasing disease prevalence, ongoing research, and the development of new diagnostic and therapeutic approaches.
Download a Free Sample To learn more about this report,
Growing Focus on Early Diagnosis and Disease-Modifying Therapies
Neurodegenerative Disease Market trends are being driven by the increasing focus on diagnosing neurological disorders at earlier stages and developing treatments that slow disease progression rather than only managing symptoms. The growing number of people affected by Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) is encouraging pharmaceutical companies to invest heavily in innovative therapies and biomarker-based diagnostics. Advances in brain imaging, blood-based biomarkers, and genetic testing are helping physicians identify patients earlier, allowing treatment to begin sooner. These developments are supporting neurodegenerative disease market growth as healthcare systems place greater emphasis on early intervention.
Rising Innovation in Gene Therapy and Precision Neurology
Neurodegenerative Disease Market trends are also being influenced by rapid progress in gene therapy, RNA-based medicines, and precision medicine. Researchers are developing treatments that target the underlying causes of neurodegenerative disorders instead of only relieving symptoms. Artificial intelligence is also being used to identify potential drug candidates and improve clinical trial efficiency, helping speed up the development of new therapies. These advancements are strengthening neurodegenerative disease market share as biotechnology and pharmaceutical companies continue investing in next-generation neurological treatments.
Rising Aging Population and Increasing Cases of Neurological Disorders
The neurodegenerative disease market is growing steadily as the number of people affected by Alzheimer's disease, Parkinson's disease, Huntington's disease, and other neurological disorders continues to rise. The growing elderly population is one of the biggest factors driving the need for effective diagnosis and treatment. Better awareness, earlier diagnosis, and increasing healthcare spending are also strengthening neurodegenerative disease market demand. In addition, governments and healthcare organizations are investing more in brain health research and patient care programs.
High Treatment Costs and Limited Curative Therapies
The neurodegenerative disease market faces challenges because most available treatments help manage symptoms rather than cure the disease. Developing new therapies requires years of research, large clinical trials, and significant investment, which increases treatment costs. In many regions, access to advanced therapies is also limited by reimbursement policies and healthcare infrastructure, making treatment less affordable for many patients.
Advances in Precision Medicine and Disease-Modifying Therapies
The neurodegenerative disease market offers strong opportunities as pharmaceutical companies invest in precision medicine, gene therapy, stem cell therapy, and targeted biologics. Researchers are also using artificial intelligence and advanced biomarkers to detect neurological diseases at earlier stages and improve treatment decisions. These innovations are expected to strengthen neurodegenerative disease market share by expanding treatment options and improving patient outcomes.
Complex Disease Biology and Long Clinical Development
The neurodegenerative disease market continues to face challenges because these disorders develop slowly and involve complex biological processes that are not yet fully understood. Clinical trials often take many years to complete, and many experimental therapies fail to show the expected results. Manufacturers also need to identify reliable biomarkers, improve early diagnosis, and meet strict regulatory requirements before bringing new treatments to market. Continued investment in research, collaboration, and innovative drug development will be essential for long-term market growth.
Request Customizationto receive a tailored report.
Alzheimer's Disease Segment Dominated the Market with 34.15% Share in 2025
The Alzheimer's disease segment dominated the global neurodegenerative disease market with a 34.15% share in 2025. The rising number of elderly people and the growing prevalence of Alzheimer's disease have increased the demand for early diagnosis and long-term treatment. Ongoing research and the launch of new therapies continue to strengthen the segment's leading position.
The multiple sclerosis and Parkinson's disease segments are also growing steadily. Better awareness, earlier diagnosis, and improved access to disease-modifying therapies are helping patients manage these conditions more effectively. Increasing healthcare spending and continuous research into advanced treatments are supporting growth across both segments.
The others segment is also expanding as research into rare neurodegenerative disorders continues to advance. Growing investment in neuroscience, precision medicine, and innovative drug development is expected to create new opportunities across a wider range of neurological conditions.
Immunomodulator Segment Dominated the Market with 46.8% Share in 2025
The immunomodulator segment dominated the global neurodegenerative disease market with a 46.8% share in 2025. These drugs are widely used, particularly in the treatment of multiple sclerosis, as they help regulate the immune system and slow disease progression. Their proven clinical benefits and increasing use in long-term disease management continue to drive demand.
The vesicular monoamine transporter 2 (VMAT2) and others segments are also growing steadily. VMAT2 inhibitors are increasingly used to manage movement disorders associated with neurological diseases, while the others category includes a wide range of medicines developed for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
Ongoing clinical trials, improved understanding of disease mechanisms, and the development of targeted therapies are expected to support growth across all drug categories over the forecast period.
Oral Segment Dominated the Market with 55.65% Share in 2025
The oral segment dominated the global neurodegenerative disease market with a 55.65% share in 2025. Oral medicines remain the preferred treatment option because they are easy to use, improve patient convenience, and support long-term treatment for chronic neurological disorders. Their widespread availability continues to make this the largest route of administration.
The intravenous (IV) delivery segment is growing steadily as more advanced biologic therapies and disease-modifying treatments require hospital-based administration. IV therapies are increasingly used for patients who need specialized treatment or cannot achieve the desired results with oral medicines.
The others segment also continues to expand with the development of alternative drug delivery methods, including injectable and transdermal therapies. Advances in drug delivery technologies and the introduction of innovative treatment options are expected to improve patient outcomes and support growth across all routes of administration.
Speak to an Analystto discuss market opportunities.
North America neurodegenerative disease market accounted for 42.35% of the global market, reaching USD 25.01 billion in 2025, and is projected to grow at a CAGR of 6.54% during the forecast period. The market is expanding because of the growing number of people affected by Alzheimer's, Parkinson's, and other neurological disorders. Strong healthcare infrastructure, increasing investment in neuroscience research, and the availability of advanced treatment options continue to support market growth across the region.
The U.S. market was valued at USD 21.26 billion in 2025, making it the largest contributor in North America. Rising cases of age-related neurological disorders, strong clinical research activity, and increasing adoption of innovative therapies continue to drive market growth.
Canada's market reached USD 3.75 billion in 2025. Growing healthcare spending, increasing awareness of neurological disorders, and expanding access to specialized treatments continue to support steady market growth.
Europe neurodegenerative disease market accounted for 28.15% of the global market, reaching USD 16.63 billion in 2025, and is expected to register a CAGR of 6.31% during the forecast period. The region is seeing steady growth due to its aging population, increasing diagnosis rates, and continued investment in neurological research. Better access to healthcare services and advanced therapies is also supporting market expansion.
Germany's market accounted for USD 4.82 billion in 2025. A strong healthcare system, increasing research on neurological diseases, and growing demand for advanced treatment options continue to support market growth.
The UK market was valued at USD 3.33 billion in 2025. Rising awareness of neurological health, increasing healthcare investment, and expanding research programs continue to contribute to market growth.
Asia Pacific neurodegenerative disease market accounted for 20.45% of the global market, valued at USD 12.08 billion in 2025, and is projected to register a CAGR of 8.12% during the forecast period. A growing elderly population, improving healthcare infrastructure, and better access to neurological care are driving market growth. Governments across the region are also investing more in healthcare services and medical research.
Japan's market generated USD 2.17 billion in 2025. The country's aging population, advanced healthcare system, and strong focus on neurological research continue to support market growth.
China's market accounted for USD 6.28 billion in 2025, representing the largest share within Asia Pacific. Rising healthcare spending, a large patient population, and increasing investment in neurological disease treatment continue to drive market growth.
Latin America neurodegenerative disease market accounted for 5.25% of the global market, reaching USD 3.10 billion in 2025, and is projected to grow at a CAGR of 6.74% during the forecast period. Improving healthcare services, rising awareness of neurological disorders, and better access to diagnosis and treatment are supporting market growth across the region.
Brazil's market reached USD 1.58 billion in 2025. Growing healthcare investments, increasing diagnosis of neurological conditions, and expanding access to specialist care continue to create growth opportunities.
Middle East & Africa neurodegenerative disease market accounted for 3.8% of the global market, totaling USD 2.24 billion in 2025, and is anticipated to grow at a CAGR of 5.96% during the forecast period. Expanding healthcare infrastructure, improving neurological care services, and rising awareness of age-related diseases are supporting market growth across the region.
The UAE market was valued at USD 0.81 billion in 2025. Government investment in healthcare, increasing access to advanced neurological treatments, and growing focus on early diagnosis continue to support market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com